Compounds > 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol
Page last updated: 2024-09-03

4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol and Basal Ganglia Diseases

4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol has been researched along with Basal Ganglia Diseases in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Braun, V; Meyer, FP; Neuhof, S; Ulrich, S1

Trials

1 trial(s) available for 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol and Basal Ganglia Diseases

ArticleYear
Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
    International clinical psychopharmacology, 1999, Volume: 14, Issue:4

    Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Interactions; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia

1999